Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

MLA

Denduluri N, et al. “Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients with Metastatic Breast Cancer Previously Untreated with Taxanes.” Journal of Clinical Oncology, vol. 25, no. 23, Aug. 2007, pp. 3421–27. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=105954152&authtype=sso&custid=ns315887.

APA

Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U, Chow CK, Steinberg SM, Yang SX, & Swain SM. (2007). Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. Journal of Clinical Oncology, 25(23), 3421–3427.

Chicago

Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U, Chow CK, Steinberg SM, Yang SX, and Swain SM. 2007. “Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients with Metastatic Breast Cancer Previously Untreated with Taxanes.” Journal of Clinical Oncology 25 (23): 3421–27. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=105954152&authtype=sso&custid=ns315887.